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1. INTRODUCTION {#cam41548-sec-0001}
===============

Gastric cancer (GC) is the fourth most common malignancy and the second most common cause of cancer‐related deaths worldwide.[1](#cam41548-bib-0001){ref-type="ref"}, [2](#cam41548-bib-0002){ref-type="ref"} Therefore, accurate evaluation of prognosis in patients with GC may contribute to the development of individualized treatment programs and improve patient prognoses. Recently, nutritional status has been reported as a prognostic factor in patients with cancer.[3](#cam41548-bib-0003){ref-type="ref"}, [4](#cam41548-bib-0004){ref-type="ref"}, [5](#cam41548-bib-0005){ref-type="ref"}, [6](#cam41548-bib-0006){ref-type="ref"}, [7](#cam41548-bib-0007){ref-type="ref"}, [8](#cam41548-bib-0008){ref-type="ref"}, [9](#cam41548-bib-0009){ref-type="ref"}

Sarcopenia, a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, results in a decline in function, poor quality of life, and death.[10](#cam41548-bib-0010){ref-type="ref"}, [11](#cam41548-bib-0011){ref-type="ref"} Although weight can reflect nutritional status, sarcopenia (the loss of muscle mass) is a more accurate and quantitative indicator of frailty (nutritional status),[12](#cam41548-bib-0012){ref-type="ref"} and the effectiveness of sarcopenia (low skeletal mass index (SMI)) in predicting prognosis in GC has been widely documented.[5](#cam41548-bib-0005){ref-type="ref"}, [13](#cam41548-bib-0013){ref-type="ref"}, [14](#cam41548-bib-0014){ref-type="ref"}, [15](#cam41548-bib-0015){ref-type="ref"}, [16](#cam41548-bib-0016){ref-type="ref"} The CONUT score, derived from serum albumin (ALB), total lymphocyte count (TLC), and cholesterol measurements, is an effective tool for assessing the status of immune nutrition.[17](#cam41548-bib-0017){ref-type="ref"} The Controlling Nutritional Status (CONUT) score is a prognostic factor for various cancers, including GC.[8](#cam41548-bib-0008){ref-type="ref"}, [18](#cam41548-bib-0018){ref-type="ref"}, [19](#cam41548-bib-0019){ref-type="ref"}, [20](#cam41548-bib-0020){ref-type="ref"} Nevertheless, no studies have determined whether SMI or the CONUT score is a better predictor of long‐term prognosis in GC.

Therefore, the aim of this study was to compare the ability of preoperative SMI and the CONUT score to predict long‐term survival in GC after radical gastrectomy (RG).

2. MATERIALS AND METHODS {#cam41548-sec-0002}
========================

2.1. Materials {#cam41548-sec-0003}
--------------

From a prospective database, 864 patients undergoing radical surgery for GC at Fujian Medical University Union Hospital (FMUUH) between 2010 and 2011 were identified. The exclusion criteria for this study were as follows: T4b patients (n = 31), intraoperative evidence of peritoneal tumor dissemination or distant metastasis (n = 9), patients with no available computed tomography (CT) images or with preoperative CT images older than 30 days (n = 235), incomplete clinical and pathologic data (n = 20), gastric stump carcinoma (n = 22), and preoperative neoadjuvant chemotherapy (n = 15). Ultimately, 532 patients were included in this study (Figure [S1](#cam41548-sup-0001){ref-type="supplementary-material"}). Laboratory blood test data were collected within 1 week before surgery, including preoperative ALB and hemoglobin (HB) levels as well as lymphocyte counts and cholesterol concentrations. The type of surgical resection and the extent of lymph node dissection were selected according to the Japanese gastric cancer treatment guidelines,[21](#cam41548-bib-0021){ref-type="ref"} and the seventh corresponding edition of the American Joint Committee on Cancer (AJCC) Staging Manual was used to determine the disease stage.[22](#cam41548-bib-0022){ref-type="ref"} Patients with stage II‐III GC were advised to undergo adjuvant chemotherapy based on fluorine.[23](#cam41548-bib-0023){ref-type="ref"}, [24](#cam41548-bib-0024){ref-type="ref"} The study was approved by the FMUUH Institutional Review Board.

2.2. Measurement and grouping of SMI {#cam41548-sec-0004}
------------------------------------

Abdominal CT images were obtained from the computer center of the hospital, and skeletal muscle parameters were measured under the guidance of a professional radiologist. With Software Osirix version 3.3 (32‐bit; <http://www.osirix-viewer.com>),[25](#cam41548-bib-0025){ref-type="ref"} the third lumbar vertebra (L3) was set as a landmark, and two consecutive slices were selected to measure the cross‐sectional areas of the skeletal muscle. The mean value of two consecutive images was computed for each patient. The muscles in the L3 region include the rectus abdominis, psoas, quadratus lumborum, paraspinal, transverse abdominal, external oblique, internal oblique, and rectus abdominis muscles. Cross‐sectional skeletal muscle area was measured according to attenuation thresholds of −29 to +150 Hounsfield units (HU).[26](#cam41548-bib-0026){ref-type="ref"} Muscle areas were normalized for height (m^2^) to obtain the L3 SMI (cm^2^/m^2^).[27](#cam41548-bib-0027){ref-type="ref"} According to a previous study conducted by our center,[16](#cam41548-bib-0016){ref-type="ref"} 32.5 cm^2^/m^2^ for men and 28.6 cm^2^/m^2^ for women were defined as low SMI. Ultimately, 91 patients (17.1%) with low SMI and 441 patients with high SMI (82.9%) were enrolled in the study.

2.3. Definition and grouping of the CONUT score {#cam41548-sec-0005}
-----------------------------------------------

The CONUT score was calculated based on serum ALB concentration, peripheral lymphocyte count, and peripheral cholesterol concentration (Table [S1](#cam41548-sup-0002){ref-type="supplementary-material"}). Based on the total scores for the three parameters, nutritional status was categorized as normal nutrition, light malnutrition, moderate malnutrition, or severe malnutrition.[17](#cam41548-bib-0017){ref-type="ref"} Because we identified only four patients with severe malnutrition in our study, we integrated moderate and severe malnutrition into a single CONUT group for all subsequent analyses.[18](#cam41548-bib-0018){ref-type="ref"} Ultimately, 291 patients (54.7%) were included in the normal nutrition group, 183 patients in the light malnutrition group (34.4%), and 58 patients in the moderate or severe malnutrition group (10.9%).

2.4. Follow‐up {#cam41548-sec-0006}
--------------

All the patients were followed up by telephone interview, outpatient visits, and letters. All surviving patients were followed up for more than 5 years. All patients were monitored postoperatively by physical examination and laboratory tests, including tests for tumor markers (such as carcinoembryonic antigen (CEA) and carbohydrate antigenic determinant (CA) 19‐9), every 3 months for the first 2 years, every 6 months for the next 3 years, and annually thereafter. In addition, examinations, including chest radiography, abdominopelvic CT, and endoscopy, were performed at least once per year. If necessary, further evaluations, such as positron emission tomography or magnetic resonance imaging, were initiated to better identify recurrence.

2.5. Statistical analysis {#cam41548-sec-0007}
-------------------------

Statistical analyses were performed with SPSS software, version 18.0 (SPSS Inc., Chicago, IL, USA), and R software, version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria). The significance tests used were Student\'s *t* test for continuous variables and the chi‐square test or Fisher\'s exact test for categorical variables. The relationships among studied parameters were examined using Spearman\'s correlation coefficient. A correlation was considered weak with coefficient values \<0.5 and strong with values \>0.8. The Kaplan‐Meier method was used to analyze overall survival (OS) and recurrence‐free survival (RFS), and the differences were assessed with log‐rank tests. A Cox proportional‐hazard model was used to identify variables with significant independent relationships with OS and RFS. Two‐tailed *P* values \<.05 were considered statistically significant.

3. RESULTS {#cam41548-sec-0008}
==========

3.1. Clinicopathological data {#cam41548-sec-0009}
-----------------------------

The clinical and pathological data of the patients are shown in Table [1](#cam41548-tbl-0001){ref-type="table"}. Age, female sex, tumor size, tumor‐node‐metastasis (TNM) stage, comorbidities, and American Society of Anesthesiologists (ASA) status were all significantly higher in patients with low SMI than in those with high SMI. BMI, HB, ALB, and lymphocyte count were significantly lower in patients with low SMI than in those with high SMI. Conversely, SMI was not affected by tumor site, histological type, cholesterol concentration, operation method, type of resection, type of reconstruction, surgical duration, intraoperative blood loss, neurovascular invasion, or adjuvant chemotherapy. There were significant differences in age, BMI, tumor size, TNM, HB, ALB, lymphocyte count, cholesterol concentration, ASA, type of resection, and intraoperative blood loss in patients with different nutritional statuses. However, there were no significant differences in tumor site, histological type, comorbidities, operation method, type of reconstruction, neurovascular invasion, or adjuvant chemotherapy.

###### 

Clinicopathological characteristics of 532 patients with gastric cancer undergoing radical gastrectomy

  Variable                    All            SMI             COUNT score                                                                
  --------------------------- -------------- --------------- -------------- ------------ -------------- --------------- --------------- --------
  Age (y)                     61.1 (11.5)    68.4 (11.4)     59.6 (10.9)    \<.001       58.8 (11.1)    62.5 (11.4)     67.7 (10.3)     \<.001
  Gender                                                                                                                                
  Female                      129 (24.2)     41 (45.1)       88 (20.0)      \<.001       72 (24.7)      36 (19.7)       21 (36.2)       .036
  Male                        403 (75.8)     50 (54.9)       353 (80.0)     219 (75.3)   147 (80.3)     37 (63.8)                       
  BMI (kg/m^2^)               21.9 (3.5)     20 (2.7)        22.3 (3.5)     \<.001       22.3 (3.5)     21.3 (2.9)      21.7 (4.6)      .012
  Tumor site                                                                                                                            
  Upper                       159 (29.9)     27 (29.7)       132 (29.9)     .96          79 (27.1)      65 (35.5)       15 (25.9)       .119
  Not upper                   373 (70.1)     64 (70.3)       309 (70.1)     212 (72.9)   118 (64.5)     43 (74.1)                       
  Tumor size (cm)             4.5 (2.5)      3.2 (2.0)       4.8 (2.5)      \<.001       4.8 (2.5)      4.1 (2.3)       4.4 (2.7)       .006
  TNM stage                                                                                                                             
  I                           165 (31)       16 (17.6)       149 (33.8)     .001         111 (38.1)     45 (24.6)       9 (15.5)        .001
  II                          123 (23.1)     17 (18.7)       106 (24.0)     63 (26.6)    46 (25.1)      14 (24.1)                       
  III                         244 (45.9)     58 (63.7)       186 (42.2)     117 (40.2)   92 (50.3)      35 (60.3)                       
  Histological type                                                                                                                     
  Differentiated              156 (29.3)     21 (23.1)       135 (30.6)     .151         88 (30.2)      50 (27.3)       18 (31)         .758
  Undifferentiated            376 (70.7)     70 (76.9)       306 (69.4)     203 (69.8)   133 (72.7)     40 (69)                         
  Comorbidities                                                                                                                         
  No                          390 (73.3)     55 (60.4)       335 (76)       .002         217 (74.6)     133 (72.7)      40 (69)         .659
  Yes                         142 (26.7)     36 (39.6)       106 (24.0)     74 (25.4)    50 (27.3)      18 (31)                         
  HB (g/dL)                   12.5 (2.1)     11.4 (2.6)      12.8 (2.5)     \<.001       13.5 (2.1)     12.0 (2.3)      9.2 (2.5)       \<.001
  ALB (g/dL)                  3.8 (0.5)      3.7 (06)        3.9 (0.5)      .004         4.1 (0.3)      3.7 (0.4)       2.9 (0.5)       \<.001
  Lymphocyte (mm^3^)          1770 (620)     1530 (680)      1820 (600)     \<.001       2020 (530)     1540 (610)      1280 (510)      \<.001
  Cholesterol (mg/dL)         189.5 (85.8)   182.7 (53.4)    190.9 (91.7)   .405         208.1 (37.6)   178.0 (130.8)   131.9 (34.9)    \<.001
  ASA                                                                                                                                   
  I                           202 (38)       19 (20.9)       183 (41.5)     .001         130 (44.7)     66 (36.1)       6 (10.3)        \<.001
  II                          312 (59.2)     69 (75.8)       246 (55.8)     154 (52.9)   111 (60.7)     50 (86.2)                       
  III                         15 (2.8)       3 (3.3)         12 (2.7)       7 (2.4)      6 (3.3)        2 (3.4)                         
  Operation method                                                                                                                      
  Open                        76 (14.3)      15 (16.5)       61 (13.8)      .51          36 (12.4)      30 (16.4)       10 (17.2)       .327
  Laparoscopic                456 (85.7)     76 (83.5)       380 (86.2)     255 (87.6)   153 (83.6)     48 (82.9)                       
  Type of resection                                                                                                                     
  Subtotal gastrectomy        297 (55.8)     49 (53.8)       248 (56.2)     .676         176 (60.5)     88 (48.1)       33 (56.9)       .03
  Total gastrectomy           235 (44.2)     42 (46.2)       193 (43.8)     115 (39.5)   95 (51.9)      25 (43.1)                       
  Type of reconstruction                                                                                                                
  Billroth I                  250 (47)       41 (45.1)       209 (47.6)     .776         150 (51.5)     73 (39.9)       27 (46.6)       .22
  Billroth II                 34 (6.4)       8 (8.8)         26 (5.9)       16 (5.5)     14 (7.7)       4 (6.9)                         
  Roux‐en‐Y                   235 (44.2)     40 (44)         195 (44.2)     116 (39.9)   93 (50.8)      26 (44.8)                       
  Other                       13 (2.4)       2 (2.1)         11 (2.5)       9 (3.1)      3 (1.6)        1 (1.7)                         
  Surgical durations          189.5 (85.8)   1856.0 (67.2)   183.4 (58.1)   .706         177.5 (56.9)   191.9 (64.8)    190.0 (53.8)    .027
  Intraoperative blood loss   96.2 (192.3)   79.1 (66.5)     99.7 (208.9)   .353         81.6 (110.1)   98.6 (132.3)    161.6 (470.5)   .015
  Neurovascular invasion                                                                                                                
  No                          400 (75.2)     64 (70.3)       336 (76.2)     .239         229 (78.7)     129 (70.5)      42 (72.4)       .115
  Yes                         132 (24.8)     27 (29.7)       105 (23.8)     62 (21.3)    54 (29.5)      16 (27.6)                       
  Adjuvant chemotherapy                                                                                                                 
  No                          280 (52.6)     46 (50.5)       234 (53.1)     .662         157 (54.0)     92 (50.3)       31 (53.4)       .731
  Yes                         252 (47.4)     45 (49.5)       207 (46.9)     134 (46.0)   91 (49.7)      27 (46.4)                       

ALB, albumin; ASA, American Society of Anesthesiologists; BMI, body mass index; COUNT, controlling nutritional status; HB, hemoglobin; SMI, skeletal muscle index.

John Wiley & Sons, Ltd

3.2. Correlation analysis {#cam41548-sec-0010}
-------------------------

Spearman\'s correlation analysis showed weak correlations of SMI with ALB, lymphocyte count, and cholesterol (all *r* ~s ~\< 0.5) (Table [2](#cam41548-tbl-0002){ref-type="table"}).

###### 

Correlation between measurements of preoperative SMI and CONUT scores in patients with gastric cancer

  Correlation coefficient (Spearman\'s p)   SMI
  ----------------------------------------- -------
  ALB                                       0.136
  Lymphocyte                                0.272
  Cholesterol                               0.033

ALB, albumin; COUNT, controlling nutritional status; SMI, skeletal muscle index.

John Wiley & Sons, Ltd

3.3. SMI, CONUT score and survival {#cam41548-sec-0011}
----------------------------------

The median duration of follow‐up was 60 months (range 2‐76 months). The 5‐year OS and RFS after surgery in patients with low SMI were significantly worse than those in patients with high SMI (41.30% vs 68%, *P* \< .001; 42.60%, vs 66.2%, *P* \< .001). Patients with normal nutrition had better 5‐year OS and RFS than did those with light malnutrition (71.40% vs 53.20%, *P* \< .001; 70% vs 51.60%, *P* \< .001), and these metrics were also better than those in patients with moderate or severe malnutrition (71.40% vs 54.50%, *P* = .006; 70% vs 55.20%; *P* = .017). However, there were no significant differences in 5‐year OS and RFS between patients with light malnutrition and those with moderate or severe malnutrition (*P* = .726) (Figure [1](#cam41548-fig-0001){ref-type="fig"}).

![Kaplan‐Meier survival curves for overall survival (OS) according to SMI (A) and the CONUT score (C); Kaplan‐Meier survival curves for recurrence‐free survival (RFS) according to SMI (B) and the CONUT score (D)](CAM4-7-3537-g001){#cam41548-fig-0001}

In univariate analysis, SMI, the CONUT score, age, tumor site, TNM, HB, ASA, type of resection, type of reconstruction, surgical duration, neurovascular invasion, and adjuvant chemotherapy were associated with 5‐year OS. Regarding 5‐year RFS, univariate analysis showed that SMI, the CONUT score, age, tumor site, TNM, histological type, type of resection, type of reconstruction, surgical duration, neurovascular invasion, and adjuvant chemotherapy were significantly associated (Table [3](#cam41548-tbl-0003){ref-type="table"}). In multivariate analysis, only TNM and SMI were independent prognostic factors for 5‐year OS and RFS (Table [3](#cam41548-tbl-0003){ref-type="table"}).

###### 

Uni‐ and multivariate analyses of factors associated with 5‐year overall survival (OS) and recurrence‐free survival (RFS) rates in patients with gastric cancer

  Variable                         Univariate analysis 5‐year OS   Multivariate analysis 5‐year OS   Univariate analysis 5‐year RFS   Multivariate analysis 5‐year RFS                                    
  -------------------------------- ------------------------------- --------------------------------- -------------------------------- ---------------------------------- ----------- -------- ----------- --------
  SMI                                                                                                                                                                                                     
  High                             Reference                       \<.001                            Reference                        .002                               Reference   \<.001   Reference   .012
  Low                              2.337 (1.702‐2.309)             1.704 (1.209‐2.403)               2.125 (1.545‐2.925)              1.553 (1.101‐2.189)                                                 
  COUNT Score                                                                                                                                                                                             
  Normal                           Reference                       \<.001                            Reference                        .173                               Reference   \<.001   Reference   .137
  Light                            1.856 (1.367‐2.519)             1.360 (0.984‐1.879)               1.837 (1.362‐2.478)              1.376 (1.005‐1.884)                                                 
  Moderate or severe               1.839 (1.183‐2.859)             1.266 (0.753‐2.126)               1.703 (1.091‐2.659)              1.154 (0.726‐1.836)                                                 
  Age (y)                                                                                                                                                                                                 
  \<65                             Reference                       .002                              Reference                        .766                               Reference   .006     Reference   .473
  ≥65                              1.563 (1.176‐2.078)             1.054 (0.733‐1.517)               1.486 (1.123‐1.968)              1.124 (0.817‐1.547)                                                 
  Gender                                                                                                                                                                                                  
  Female                           Reference                       .131                                                                                                  Reference   .051                 
  Male                             0.783 (0.571‐1.075)                                               0.736 (0.541‐1.002)                                                                                  
  BMI (kg/m^2^)                                                                                                                                                                                           
  \<25                             Reference                       .086                                                                                                  Reference   .156                 
  ≥25                              0.654 (0.402‐1.063)                                               0,716 (0.451‐1.136)                                                                                  
  Tumor site                                                                                                                                                                                              
  Upper                            Reference                       .008                              Reference                        .303                               Reference   0.005    Reference   .103
  Not upper                        0.673 (0.501‐0.903)             0.824 (0.569‐1.192)               0.657 (0.491‐0.878)              0.736 (0.509‐1.064)                                                 
  Tumor size (cm)                                                                                                                                                                                         
  \<5.0                            Reference                       .076                                                                                                  Reference   0.100                
  ≥5.0                             0.768 (0.573‐1.028)                                               0.786 (0.591‐1.047)                                                                                  
  TNM stage                                                                                                                                                                                               
  I                                Reference                       \<.001                            Reference                        \<.001                             Reference   \<.001   Reference   \<.001
  II                               2.125 (1.165‐3.876)             1.931 (1.042‐3.576)               2.260 (1.267‐4.030)              2.029 (1.120‐3.678)                                                 
  III                              8.331 (5.009‐13.612)            7.520 (4.457‐12.690)              8.178 (5.065‐13.202)             7.337 (4.365‐12.334)                                                
  Histological type                                                                                                                                                                                       
  Differentiate                    Reference                       .063                                                                                                  Reference   .026     Reference   .784
  Undifferentiated                 1.362 (0.984‐1.884)                                               1.447 (1.045‐2.004)              0.953 (0.677‐1.342)                                                 
  Comorbidities                                                                                                                                                                                           
  No                               Reference                       .352                                                                                                  Reference   .555                 
  Yes                              1.160 (0.849‐1.583)                                               1.098 (0.806‐1.496)                                                                                  
  HB (g/L)                                                                                                                                                                                                
  \>90                             Reference                       .036                              Reference                        .702                               Reference   .056                 
  ≤90                              1.535 (1.028‐2.292)             0.911 (0.564‐1.471)               1.477 (0.990‐2.204)                                                                                  
  ASA                                                                                                                                                                                                     
  I                                Reference                       .044                              Reference                        .435                               Reference   .102                 
  II                               1.483 (1.089‐2.021)             1.277 (0.880‐1.854)               1.377 (1.018‐1.863)                                                                                  
  III                              1.395 (0.602‐3.231)             1.189 (0.480‐2.945)               1.501 (0.688‐3.278)                                                                                  
  Operation method                                                                                                                                                                                        
  Open                             Reference                       .173                                                                                                  Reference   .218                 
  Laparoscopic                     0.768 (0.525‐1.123)                                               0.788 (0.540‐1.151)                                                                                  
  Type of resection                                                                                                                                                                                       
  Subtotal gastrectomy             Reference                       \<.001                            Reference                        .802                               Reference   \<.001   Reference   .944
  Total gastrectomy                1.944 (1.460‐2.591)             1.089 (0.559‐2.123)               1.827 (1.379‐2.421)              1.023 (0.538‐1.945)                                                 
  Type of reconstruction                                                                                                                                                                                  
  Billroth I                       Reference                       \<.001                            Reference                        .191                               Reference   \<.001   Reference   .225
  Billroth II                      2.582 (1.510‐4.414)             1.843 (1.044‐3.254)               2.562 (1.522‐4.313)              1.745 (1.008‐3.019)                                                 
  Roux‐en‐Y                        2.124 (1.555‐2.901)             1.158 (0.568‐2.362)               2.042 (1.505‐2.770)              1.077 (0.544‐2.132)                                                 
  Other                            1.199 (0.436‐3.294)             0.926 (0.314‐2.735)               1.122 (0.409‐3.077)              0.892 (0.307‐2.590)                                                 
  Surgical durations (min)                                                                                                                                                                                
  \<180                            Reference                       .007                              Reference                        .237                               Reference   .005     Reference   .189
  ≥180                             1.502 (1.118‐2.019)             1.204 (0.885‐1.637)               1.519 (1.135‐2.032)              1.224 (0.905‐1.656)                                                 
  Intraoperative blood loss (mL)                                                                                                                                                                          
  \<50                             Reference                       0.380                                                                                                 Reference   .342                 
  ≥50                              1.402 (0.659‐2.983)                                               1.442 (0.678‐3.066)                                                                                  
  Neurovascular invasion                                                                                                                                                                                  
  No                               Reference                       .008                              Reference                        .442                               Reference   .007     Reference   .406
  Yes                              1.523 (1.119‐2.074)             1.133 (0.824‐1.557)               1.516 (1.118‐2.057)              1.141 (0.836‐1.558)                                                 
  Adjuvant chemotherapy                                                                                                                                                                                   
  No                               Reference                       .036                              Reference                        .062                               Reference   .005     Reference   .281
  Yes                              1.357 (1.021‐1.084)             0.747 (0.552‐1.012)               1.492 (1126‐1.976)               0.849 (0.631‐1.143)                                                 

ASA, American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval; COUNT, controlling nutritional status; HB, hemoglobin; HR, hazard ratio; OS, overall survival; RFS, recurrence‐free survival; SMI, skeletal muscle index.

John Wiley & Sons, Ltd

4. DISCUSSION {#cam41548-sec-0012}
=============

The determinants of cancer progression and prognosis are multifaceted, and increasing attention has been paid to the relationship between cancer and malnutrition.[3](#cam41548-bib-0003){ref-type="ref"}, [28](#cam41548-bib-0028){ref-type="ref"} Over the past few decades, malnutrition has been associated with a poor response to treatment, decreased quality of life, a higher risk of chemotherapy side effects, and worse prognosis.[4](#cam41548-bib-0004){ref-type="ref"}, [5](#cam41548-bib-0005){ref-type="ref"}, [29](#cam41548-bib-0029){ref-type="ref"}, [30](#cam41548-bib-0030){ref-type="ref"}

CT imaging to assess body composition has been widely used in the field of cancer treatment and research due to its universality, high accuracy, and low incremental costs. Sarcopenia (low SMI), a multifactorial clinical condition, is closely associated with nutritional deficiencies.[5](#cam41548-bib-0005){ref-type="ref"}, [31](#cam41548-bib-0031){ref-type="ref"} After analyzing the survival data of 937 GC patients with TNM stage II or III who underwent RG, Zhuang et al[13](#cam41548-bib-0013){ref-type="ref"} concluded that sarcopenia (low SMI) was an independent risk factor for OS and RFS. Kensuke\'s studies suggested that sarcopenia (low SMI) was associated with a negative prognosis in esophagogastric junction cancer or upper GC.[14](#cam41548-bib-0014){ref-type="ref"} In addition, previous studies in our center have demonstrated that combining sarcopenia (low SMI) with the cT and cN system could accurately predict long‐term survival after RG for GC.[16](#cam41548-bib-0016){ref-type="ref"}

The CONUT score has been established as a useful tool to evaluate nutritional status,[17](#cam41548-bib-0017){ref-type="ref"} and it is closely related to the prognosis of various cancers.[18](#cam41548-bib-0018){ref-type="ref"}, [19](#cam41548-bib-0019){ref-type="ref"}, [20](#cam41548-bib-0020){ref-type="ref"} The CONUT score not only reflects the nutritional status of patients with GC but also predicts long‐term OS after surgery for GC.[8](#cam41548-bib-0008){ref-type="ref"} Takagi et al[19](#cam41548-bib-0019){ref-type="ref"} suggested that the CONUT score was a reliable predictor of long‐term prognosis after hepatectomy for hepatocellular carcinoma. In addition, the predictive ability of the CONUT score is better than that of classic indicators, such as the neutrophil to lymphocyte ratio (NLR), prognostic nutritional index (PNI), and modified Glasgow Prognostic Score (mGPS).[8](#cam41548-bib-0008){ref-type="ref"}, [19](#cam41548-bib-0019){ref-type="ref"} However, whether the predictive power of the CONUT score is superior to that of sarcopenia has not been previously reported.

In this study, the CONUT score and SMI were prognostic factors for OS and RFS after RG according to univariate analysis, but in multivariate analysis, only SMI remained an independent prognostic factor for OS and RFS. Although Kuroda et al[8](#cam41548-bib-0008){ref-type="ref"} found that the CONUT score was an independent risk factor for long‐term survival after surgery for GC and was superior to NLR and mGPS, it was not included among the factors for SMI. The present study included both the CONUT score and SMI and revealed that the prognostic ability of SMI was better than that of the CONUT score. The possible reasons for this finding are as follows. The CONUT score is calculated based on plasma ALB concentration, total peripheral lymphocyte count, and total cholesterol concentration. Serum ALB concentration is affected not only by nutritional status but also by changes in body fluid volume, such as dehydration, fluid retention, and chronic disease‐induced inflammatory responses.[32](#cam41548-bib-0032){ref-type="ref"}, [33](#cam41548-bib-0033){ref-type="ref"} Therefore, the CONUT score is more easily influenced by outside interference. In contrast, SMI is a highly objective measurement based on the use of CT scans to measure body composition, with a reported measurement error of approximately 1.4%.[26](#cam41548-bib-0026){ref-type="ref"} Moreover, SMI markers are relatively stable, and rapid fluctuations in skeletal muscle mass are unlikely to occur over a short period of time. This objectivity and stability are conducive to correctly predicting patient prognosis. In contrast to Yoshida et al\'s study,[18](#cam41548-bib-0018){ref-type="ref"} there were no statistically significant differences in 5‐year OS and RFS between patients with light malnutrition and those with moderate or severe malnutrition. This outcome suggests that the ability of the CONUT score to determine the long‐term survival of patients with light and moderate or severe malnutrition remains unproven. This finding might also be associated with the small number of patients with severe malnutrition (n = 58, 10.9%) in our study. These possible explanations require further research to confirm. Nevertheless, SMI is currently a better predictor than the CONUT score of long‐term survival after radical surgery for patients with GC.

We acknowledge several potential limitations of the present study. First, 235 patients were excluded from the study because they had no available abdominal CT data, which might have resulted in selection bias. Second, the design was retrospective, and the cases were obtained from a single center; therefore, the findings must be confirmed in prospective studies. Nevertheless, for the first time, this study compared the prognostic value of preoperative SMI and the CONUT score to predict long‐term outcomes in GC, revealing that SMI was a more stable and objective predictor than the CONUT score.

5. CONCLUSION {#cam41548-sec-0013}
=============

Skeletal muscle index based on preoperative CT images is superior to the CONUT score in terms of prognostic value in GC after RG. Therefore, preoperative SMI should be included in preoperative risk assessment, although this conclusion must be confirmed by a large‐scale, prospective validation study.
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